Last reviewed · How we verify
Gemcitabine + carboplatin
Gemcitabine and carboplatin work together as a chemotherapy combination that damages cancer cell DNA through different mechanisms to inhibit tumor growth.
Gemcitabine and carboplatin work together as a chemotherapy combination that damages cancer cell DNA through different mechanisms to inhibit tumor growth. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.
At a glance
| Generic name | Gemcitabine + carboplatin |
|---|---|
| Also known as | Background Gemcitabine-based Chemotherapy Regimen, Platinum based Standard of Care Chemotherapy |
| Sponsor | AstraZeneca |
| Drug class | Chemotherapy combination (nucleoside analog + platinum agent) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and apoptosis. Carboplatin is a platinum-based alkylating agent that forms DNA cross-links, preventing replication. The combination provides synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Breast cancer
- Pancreatic cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Fatigue
- Peripheral neuropathy
- Nephrotoxicity
- Hepatotoxicity
- Alopecia
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) (PHASE2, PHASE3)
- Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (PHASE2)
- Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma (PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gemcitabine + carboplatin CI brief — competitive landscape report
- Gemcitabine + carboplatin updates RSS · CI watch RSS
- AstraZeneca portfolio CI